STOCK TITAN

Vir Biotechnology Inc - VIR STOCK NEWS

Welcome to our dedicated news page for Vir Biotechnology (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vir Biotechnology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vir Biotechnology's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.1%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.07%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
earnings
-
Vir Biotechnology Inc

Nasdaq:VIR

VIR Rankings

VIR Stock Data

1.36B
89.75M
14.29%
76.3%
3.76%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
San Francisco

About VIR

vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.